Momenta Pharmaceuticals, Inc. (MNTA)

[steveporsche]

<<"Base model, DCF analysis support $19 price objective
Our base model and $19 discounted cash flow-based PO assume no competition on Lovenox until 2013 and a generic Copaxone launch in mid-2014 (Teva’s patent expiry), with MNTA alone through 2016, which we believe is reasonable.">>

This statement from BoA is especially idiotic, as MNTA's cash balance alone under such a scenario would probably exceed $19.